SPECIAL UPDATE â PCYC â GILD Severely Restrictive Zydelig Label Underscores Imbruvicaâs Superior Profile â Reiterate BUY – Gilead received approval midday for Zydelig (idelalisib) for three blood cancers â refractory CLL, indolent FL and SLL â some what ahead of the August/September PDUFA dates. Â While the approvals were widely expected, the strict BLACK BOX[…]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.